For patients with recurrent ovarian cancer, trebananib did not improve overall survival

the Oncology Nurse Advisor take:

Amgen has announced secondary endpoint results from its TRINOVA-1 study that investigated trebananib plus paclitaxel for the treatment of patients with recurrent ovarian cancer.

The combination therapy did not show a statistically significant improvement in overall survival compared with placebo plus paclitaxel. The TRIANOVA-1 study is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial that evaluated trebananib in combination with weekly paclitaxel in women with epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Researchers randomly assigned patients to receiver either trebananib 15mg/kg intravenously weekly plus paclitaxel 80mg/m2 intravenously weekly for 3 weeks for 4-week cycles or placebo plus paclitaxel 80mg/m2 intravenously weekly for 3 weeks for 4-week cycles.

Amgen previously announced positive primary endpoint results that showed a statistically significant improvement in progression-free survival in the trebananib group, but secondary endpoint results showed a median overall survival of 19.3 months among those who received trebananib and 18.3 months among those who received placebo.

Despite the disappointing results, trebananib is also being studied in other combinations for the same three cancers. Trebananib is an investigational peptibody that ultimately inhibits angiogenesis, thereby causing cancer cell death.